0000000000162177

AUTHOR

Luis Chiva

showing 5 related works from this author

Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.

2020

Objective. To determine the factors related with diverting ileostomy performance after colorectal resection and anastomosis, in advanced ovarian cancer cytoreductive surgery. Methods. We have previously demonstrated the risk factors associated with anastomotic leak after colorectal anastomosis: Advanced age at surgery, low serum albumin level, additional bowel resections, manual anastomosis and distance of the anastomosis from the anal verge. However, use of diverting ileostomy is strongly variable and depends on individual surgeon preferences and training. Eight hospitals participated in this retrospective study. Data of 695 patients operated for ovarian cancer with primary colorectal anas…

0301 basic medicinemedicine.medical_specialtyBevacizumabAnastomotic LeakGynecologic oncologyAnastomosisStomaCohort Studies03 medical and health sciences0302 clinical medicineDiverting ileostomyOvarian cancerAnastomotic leakMedicineHumansPractice Patterns Physicians'AgedNeoplasm StagingRetrospective StudiesOvarian Neoplasmsbusiness.industryIleostomyAnastomosis SurgicalObstetrics and GynecologyRetrospective cohort studyPerioperativeCytoreduction Surgical Proceduresmedicine.diseaseNeoadjuvant TherapySurgeryBevacizumab030104 developmental biologyRisk factorsOncology030220 oncology & carcinogenesisCohortFemaleRisk factorbusinessOvarian cancerColorectal Neoplasmsmedicine.drugGynecologic oncology
researchProduct

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a G…

2011

Objectives: The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous (IP/IV) chemotherapy regimen for the treatment of patients with optimally debulked stage III ovarian cancer. Methods: Between February 2006 and November 2008, 51 consecutive patients from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy regimen. Patients received IV paclitaxel 175 mg/m2 over 3 hours on day 1, followed by IP cisplatin 100 mg/m2 (or 75 mg/m2 according to the principal investigator9s criteria) on day 2. On day 8, patients received IP paclitaxel 6…

Adultmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentNeutropeniaCarcinoma Ovarian EpithelialDrug Administration ScheduleAntineoplastic Combined Chemotherapy ProtocolsOutpatientsMedicineHumansInfusions ParenteralNeoplasms Glandular and EpithelialProspective StudiesProspective cohort studyInfusions IntravenousAgedNeoplasm StagingStage III Ovarian CancerOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseaseChemotherapy regimenSurgeryClinical trialRegimenTreatment OutcomeOncologySpainFeasibility StudiesFemaleCisplatinbusinessOvarian cancerInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

2021

This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models wer…

MaleCOVID-19 COVIDSURG COVIDSURG CANCEROutcome AssessmentIMPACTSettore MED/18 - CHIRURGIA GENERALEBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Surgery.surgeryCancer surgeryNeoplasms/classificationBIOMEDICINA I ZDRAVSTVO. Javno zdravstvo i zdravstvena zaštita.Surgical oncologyNeoplasmsAcute careCOVID-19 - epidemiologyOutcome Assessment Health CareMedicine and Health Sciences80 and overGlobal healthtimingProspective StudiesUK610 Medicine & healthProspective cohort studyCOVID-19/epidemiologyCOVIDAged 80 and overBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology.BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Kirurgija.Hazard ratioArticlesMiddle AgedOncologyAdult; Aged; Aged 80 and over; Communicable Disease Control; COVID-19; Female; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Proportional Hazards Models; Prospective Studies; SARS-CoV-2; Time-to-Treatment; Withholding Treatment/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalecancer surgeryCovid-19Life Sciences & BiomedicineMENTAL-HEALTHmental healthCohort studyHumanAdultmedicine.medical_specialtydelay3122 CancersCOVID-19 - prevention and control610 Medicine & healthCOVIDSurg CollaborativeNOTime-to-TreatmentSDG 3 - Good Health and Well-beingLockdownmedicineHumanscancer1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryLS7_4Proportional Hazards ModelsAgedScience & Technologybusiness.industrySARS-CoV-2Public healthGeneral surgeryBIOMEDICINE AND HEALTHCARE. Public Health and Health Care.COVID-193126 Surgery anesthesiology intensive care radiologyHealth CareCommunicable Disease Control/legislation & jurisprudenceProspective StudieWithholding TreatmentCOVID-19; delay; SARS-CoV-2; surgery; timing; cancer surgery;COVID-19 ; lockdowns ; cancer surgeryCommunicable Disease ControlBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija.Proportional Hazards ModelNeoplasmbusiness
researchProduct

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking sur…

2021

The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, and updated in 2020, quality indicators for advanced ovarian cancer surgery to audit and improve clinical practice in Europe and beyond. As a sequela of the continuous effort to improve oncologic care in patients with ovarian cancer, ESGO issued in 2018 a consensus guidance jointly with the European Society of Medical Oncology addressing in a multidisciplinary fashion 20 selected key questions in the management of ovarian cancer, ranging from molecular pathology to palliation in primary and relapse disease. In order to complement the above achievements and consolidate the promoted sy…

medicine.medical_specialtyEvidence-based practicebusiness.industryObstetrics and GynecologyCancerGuidelines as TopicPerioperativeDiseaseAuditCarcinoma Ovarian Epithelialmedicine.diseaseDebulkingSurgeryScientific evidenceEuropeovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologydebulking surgeryMedicineHumansFemalebusinessOvarian cancerPerioperative Period
researchProduct

Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pand…

2021

Abstract Background Surgical services are preparing to scale up in areas affected by COVID-19. This study aimed to evaluate the association between preoperative SARS-CoV-2 testing and postoperative pulmonary complications in patients undergoing elective cancer surgery. Methods This international cohort study included adult patients undergoing elective surgery for cancer in areas affected by SARS-CoV-2 up to 19 April 2020. Patients suspected of SARS-CoV-2 infection before operation were excluded. The primary outcome measure was postoperative pulmonary complications at 30 days after surgery. Preoperative testing strategies were adjusted for confounding using mixed-effects models. Results Of 8…

Lung DiseasesMalexAcademicSubjects/MED00910COVID-19/diagnosisSettore MED/18 - CHIRURGIA GENERALEneoplasms030230 surgeryminorsurgical proceduresMedical and Health SciencesLung Disease0302 clinical medicinePostoperative Complications030202 anesthesiologyaged; aged 80 and over; COVID-19; elective surgical procedures; female; humans; lung diseases; male; middle aged; Nasopharynx; neoplasms; pandemics; postoperative complications; risk assessment; SARS-CoV-2; COVID-19 nucleic acid testingNeoplasmsNasopharynx80 and over030212 general & internal medicine610 Medicine & healthLungCancerlung diseasesAged 80 and overIncidence (epidemiology)ConfoundingPulmonary ComplicationLung Diseases/*etiologyNeoplasms/surgeryGeneral MedicineMiddle AgedElective Surgical Procedures/adverse effectsOncologyElective Surgical Procedures030220 oncology & carcinogenesisCOVID-19 Nucleic Acid TestingOriginal ArticleFemalePatient SafetyAcademicSubjects/MED00010Elective Surgical Procedure6.4 SurgeryHumanCohort studymedicine.medical_specialtypreoperative caresurgical proceduresCOVID-19 nucleic acid testing.elective surgical proceduresPreoperative careRisk AssessmentArticleCOVIDSurg CollaborativeNO*COVID-19 Nucleic Acid TestingVaccine Related03 medical and health sciencesClinical ResearchBiodefensemedicineNasopharynx/*virologyHumansNasopharynx/virologyElective surgeryAdverse effectPandemicsLS7_4AgedElective Surgical ProcedurePandemicbusiness.industrySARS-CoV-2Surgery Sars Cov2PreventionNo key words availableelectivesurgical proceduresLung Diseases/etiologyEvaluation of treatments and therapeutic interventionsCancerPostoperative complicationoperativenasopharynxsurgery specialtypulmonary complicationscancer surgerysars-cov-2covid-19coronavirus pandemicCOVID-19Odds ratiomedicine.diseaseConfidence intervalSurgeryCOVID-19/*diagnosisEmerging Infectious DiseasesGood Health and Well BeingNeoplasmSurgeryPostoperative Complicationpreoperative caresurgical procedures electivesurgical procedures minorsurgical procedures operativenasopharynxsurgery specialtypulmonary complicationscancer surgerysars-cov-2covid-19coronavirus pandemicElective Surgical Procedures/*adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct